Videos

Briana Choi, PharmD, discusses results from a study evaluating the cost-effectiveness of adjunctive maintenance therapy with osimertinib in resected EGFR-positive NSCLC, finding that it varies across stages of disease.

David Barrington, MD, discusses results from a study suggesting lenvatinib plus pembrolizumab is not a cost-effective treatment option for patients with recurrent endometrial cancer.

Weijia Wang, MSc, discusses results from a study examining the association of demographics, comorbidities, chemotherapy regimen, and risk factors on the risk of developing febrile neutropenia in the first cycle of receiving pegfilgrastim...

Lincy Lal, PhD, discusses the utilization of integrated clinical and claims data to evaluate treatment patterns, resource utilization, and total costs of care during therapy for patients with newly diagnosed genitourinary cancers.

Petros Grivas, MD, PhD, discusses results from a study exploring decision-making processes regarding first-line treatment choices, testing practices and treatment eligibility determinants for patients with metastatic urothelial cancer.

Lucio Gordan, MD, discusses results from a study analyzing the impact of late dosing of two leuprolide acetate formulations on testosterone suppression for patients with prostate cancer.

Daniel Simmons, PharmD, MS, details a study comparing clinical outcomes and costs with a biomarker-guided approach and non-biomarker guided approach to first-line maintenance therapy for advanced ovarian cancer.